{"id":"https://openalex.org/W2332443634","doi":"https://doi.org/10.1097/cmr.0b013e32835f73b2","title":"Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma","display_name":"Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma","publication_year":2013,"publication_date":"2013-02-14","ids":{"openalex":"https://openalex.org/W2332443634","doi":"https://doi.org/10.1097/cmr.0b013e32835f73b2","mag":"2332443634","pmid":"https://pubmed.ncbi.nlm.nih.gov/23411478"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0b013e32835f73b2","doi":"https://doi.org/10.1097/cmr.0b013e32835f73b2","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0b013e32835f73b2","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[{"id":"https://openalex.org/I1315885867","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1315885867"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":["Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. jason_luke@dfci.harvard.edu","Accepted January 25, 2013","Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","Received August 27, 2012","aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","e-mail: [email\u00a0protected]","fax: +1 617 632 6727"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. jason_luke@dfci.harvard.edu","institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4210134579"]},{"raw_affiliation_string":"Accepted January 25, 2013","institution_ids":[]},{"raw_affiliation_string":"Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","institution_ids":["https://openalex.org/I1315885867"]},{"raw_affiliation_string":"Received August 27, 2012","institution_ids":[]},{"raw_affiliation_string":"aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 617 632 6727","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033078993","display_name":"Larry Rubinstein","orcid":"https://orcid.org/0000-0002-9720-9737","observed_orcids":["https://orcid.org/0000-0002-9720-9737"]},"institutions":[{"id":"https://openalex.org/I1315885867","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1315885867"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence V. Rubinstein","raw_affiliation_strings":["Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","Accepted January 25, 2013","Received August 27, 2012","aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","e-mail: [email\u00a0protected]","fax: +1 617 632 6727"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","institution_ids":["https://openalex.org/I1315885867"]},{"raw_affiliation_string":"Accepted January 25, 2013","institution_ids":[]},{"raw_affiliation_string":"Received August 27, 2012","institution_ids":[]},{"raw_affiliation_string":"aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 617 632 6727","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033277200","display_name":"Gary L. N. Smith","orcid":"https://orcid.org/0000-0003-3038-1345","observed_orcids":["https://orcid.org/0000-0003-3038-1345"]},"institutions":[{"id":"https://openalex.org/I1315885867","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1315885867"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary L. Smith","raw_affiliation_strings":["Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","Accepted January 25, 2013","Received August 27, 2012","aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","e-mail: [email\u00a0protected]","fax: +1 617 632 6727"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","institution_ids":["https://openalex.org/I1315885867"]},{"raw_affiliation_string":"Accepted January 25, 2013","institution_ids":[]},{"raw_affiliation_string":"Received August 27, 2012","institution_ids":[]},{"raw_affiliation_string":"aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 617 632 6727","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080736692","display_name":"S. Percy Ivy","orcid":"https://orcid.org/0000-0001-7747-072X","observed_orcids":["https://orcid.org/0000-0001-7747-072X"]},"institutions":[{"id":"https://openalex.org/I1315885867","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1315885867"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Percy Ivy","raw_affiliation_strings":["Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","Accepted January 25, 2013","Received August 27, 2012","aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","e-mail: [email\u00a0protected]","fax: +1 617 632 6727"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","institution_ids":["https://openalex.org/I1315885867"]},{"raw_affiliation_string":"Accepted January 25, 2013","institution_ids":[]},{"raw_affiliation_string":"Received August 27, 2012","institution_ids":[]},{"raw_affiliation_string":"aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 617 632 6727","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038810287","display_name":"Pamela Jo Harris","orcid":"https://orcid.org/0000-0003-0608-7912","observed_orcids":["https://orcid.org/0000-0003-0608-7912"]},"institutions":[{"id":"https://openalex.org/I1315885867","display_name":"American Society of Clinical Oncology","ror":"https://ror.org/04fy6j421","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1315885867"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela J. Harris","raw_affiliation_strings":["Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","Accepted January 25, 2013","Received August 27, 2012","aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","e-mail: [email\u00a0protected]","fax: +1 617 632 6727"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Poster previously presented at 2012 ASCO Annual Meeting, Chicago, IL, USA","institution_ids":["https://openalex.org/I1315885867"]},{"raw_affiliation_string":"Accepted January 25, 2013","institution_ids":[]},{"raw_affiliation_string":"Received August 27, 2012","institution_ids":[]},{"raw_affiliation_string":"aMelanoma Disease Center, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"bCancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 617 632 6727","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5063337705"],"corresponding_institution_ids":["https://openalex.org/I1315885867","https://openalex.org/I4210117453","https://openalex.org/I4210134579","https://openalex.org/I4210140884"],"apc_list":null,"apc_paid":null,"fwci":0.3569,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.67258921,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"23","issue":"2","first_page":"152","last_page":"158"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0071000000461936,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8740000128746033},{"id":"https://openalex.org/keywords/dacarbazine","display_name":"dacarbazine","score":0.9229999780654907},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.7559999823570251},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.9810000061988831},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.796999990940094},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5849999785423279},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.49399998784065247},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.8069999814033508}],"concepts":[{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.9391978979110718},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7953329086303711},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7555443644523621},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.6722548007965088},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6624587774276733},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6260058283805847},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6213185787200928},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5931472182273865},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5393519401550293},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.48519614338874817},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.40598058700561523},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3742596507072449},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3448147773742676},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.15835806727409363},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.11722230911254883}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/cmr.0b013e32835f73b2","doi":"https://doi.org/10.1097/cmr.0b013e32835f73b2","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0b013e32835f73b2","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:23411478","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23411478","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1494389299","https://openalex.org/W1879616740","https://openalex.org/W1917632054","https://openalex.org/W1977246223","https://openalex.org/W1979521671","https://openalex.org/W2008452038","https://openalex.org/W2020352568","https://openalex.org/W2060569900","https://openalex.org/W2097995306","https://openalex.org/W2100158834","https://openalex.org/W2102335858","https://openalex.org/W2107427969","https://openalex.org/W2109967225","https://openalex.org/W2114847324","https://openalex.org/W2128542677","https://openalex.org/W2139248078","https://openalex.org/W2142613706","https://openalex.org/W2148666312","https://openalex.org/W2149626936","https://openalex.org/W2150103321","https://openalex.org/W2155777530","https://openalex.org/W2160305793","https://openalex.org/W2160834915","https://openalex.org/W2164956805","https://openalex.org/W2167805334","https://openalex.org/W2171497508","https://openalex.org/W2417065787"],"related_works":["https://openalex.org/W2598903539","https://openalex.org/W2590500351","https://openalex.org/W2007010482","https://openalex.org/W2117138659","https://openalex.org/W2112403746","https://openalex.org/W2138239740","https://openalex.org/W2063324830","https://openalex.org/W1879616740","https://openalex.org/W2040851929","https://openalex.org/W4254358982"],"abstract_inverted_index":{"After":[0],"ipilimumab,":[1],"vemurafenib,":[2],"and":[3,35,75,120,138,143,148,158,188,244],"interleukin-2,":[4],"standard":[5],"of":[6,32,44,49,81,87,91,111,133,193,200,203,216,230,233,246],"care":[7],"chemotherapy":[8,189],"for":[9,37,207],"melanoma":[10,53,95,210],"remains":[11],"dacarbazine":[12,134,257],"(response":[13],"rate":[14],"\u223c9%).":[15],"Despite":[16],"this,":[17],"many":[18],"physicians":[19],"hesitate":[20],"to":[21,24,71,256],"refer":[22],"patients":[23,51,93,208],"phase":[25,56,84,101,164,204,234,237,248],"I":[26,57,102,165,205,235,249],"protocols":[27],"given":[28],"a":[29,109,178],"perceived":[30],"lack":[31],"clinical":[33,121,185],"benefit":[34,122,186],"potential":[36],"harm.":[38],"To":[39],"better":[40],"understand":[41],"the":[42,47,61,78,198,214,231,247],"validity":[43],"these":[45,125],"perceptions,":[46],"experience":[48],"all":[50],"with":[52,77,94,108,177,183,190,209],"treated":[54,97],"on":[55],"trials":[58,86,126,206,239,250],"sponsored":[59],"by":[60],"National":[62],"Cancer":[63],"Institute-Cancer":[64],"Therapy":[65],"Evaluation":[66],"Program":[67],"(NCI-CTEP)":[68],"from":[69,131],"1995":[70],"2011":[72],"were":[73,96,106,127,160],"analyzed":[74],"compared":[76],"pooled":[79],"results":[80],"six":[82],"contemporary":[83],"III":[85,238],"dacarbazine.":[88],"A":[89],"total":[90],"937":[92],"in":[98,124,223],"148":[99],"CTEP":[100],"trials.":[103],"The":[104],"majority":[105],"men":[107],"median":[110],"two":[112],"prior":[113,117],"therapies":[114],"(46%":[115],"receiving":[116],"dacarbazine).":[118],"Response":[119],"rates":[123],"not":[128],"clinically":[129],"different":[130],"those":[132],"(phase":[135],"I:":[136],"6.3":[137],"26.8%":[139],"vs.":[140,155,236],"dacarbazine:":[141],"8.8":[142],"27.9%)":[144],"although":[145],"grades":[146],"3":[147],"4":[149,195],"toxicity":[150,159,217,224],"was":[151,175,211,218],"significantly":[152],"higher":[153,191],"(54":[154],"28%).":[156],"Efficacy":[157],"generally":[161],"consistent":[162],"within":[163],"subgroups":[166],"(targeted":[167],"agents,":[168],"immunotherapies,":[169],"or":[170],"chemotherapeutics)":[171],"though":[172],"targeted":[173],"therapy":[174],"associated":[176],"lower":[179,184],"response":[180],"rate,":[181,187],"immunotherapy":[182],"incidence":[192],"grade":[194],"toxicity.":[196],"Thus,":[197],"perception":[199,215],"limited":[201],"efficacy":[202],"disproven,":[212],"whereas":[213],"observed.":[219],"However,":[220],"this":[221],"difference":[222],"may":[225],"have":[226],"been":[227],"largely":[228],"because":[229,245],"nature":[232],"(i.e.":[240],"more":[241],"heavily":[242],"pretreated)":[243],"often":[251],"being":[252],"multiagent":[253],"as":[254],"opposed":[255],"alone.":[258]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}